bioRxiv Science⌕ Search

Biology subjects

Ung, T. T.

Publications and source records attributed to Ung, T. T..

2 recordsLinked to original sources

AAV-mediated age- and circuit-dependent restoration of photoreceptor synaptic structure and function in α2δ4-associated retinal synaptopathy

PurposeSynaptic dysfunction and neurite remodeling are early features of many inherited retinal diseases, but whether synaptic function can be restored after circuit remodeling remains unclear. We evaluated the therapeutic potential of adeno-associated virus (AAV)-mediated 2{delta}4 gene supplementation in a mouse model of CACNA2D4-associated retinal synaptopathy. MethodsAAV8-GRK1-2{delta}4 was delivered by subretinal injection to 2{delta}4 knockout mice at neonatal, young adult, or middle-aged adult stages. Retinal function was assessed by electroretinography. Synaptic organization and circuit remodeling were evaluated by immunohistochemistry. ResultsAAV-mediated 2{delta}4 expression restored synaptic localization of Cav1.4, ELFN proteins, and mGluR6 at all treatment ages. However, circuit structure and functional rescue were age- and circuit-dependent. Neonatal treatment restored rod and cone transmission and prevented photoreceptor terminal retraction and bipolar cell dendritic sprouting. Rescue in young adults improved rod and cone circuit function but did not reverse neurite remodeling. Rescue in middle-aged mice restored cone but not rod transmission. Notably, neonatal treatment produced the highest proportion of synapses within synaptic layer, whereas adult treatment generated increasing ectopic synapses in nuclear layer. ConclusionsPhotoreceptor synaptic assembly remains plastic in remodeled retinas and can be restored by 2{delta}4 supplementation. However, rescue efficacy is influenced by age and circuits with rod circuits exhibiting a narrower therapeutic window. Synaptic molecular reassembly can occur without neurite restoration. These findings establish 2{delta}4 gene therapy as a promising treatment for CACNA2D4-associated retinal synaptopathy and reveal distinct intervention windows for synaptic assembly, neurite remodeling, and rod versus cone circuit recovery.

neuroscience↗

PRE-CLINICAL IMMUNE RESPONSE AND SAFETY EVALUATION OF THE PROTEIN SUBUNIT VACCINE NANOCOVAX FOR COVID-19

The Coronavirus disease-2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has become a dire global health concern. The development of vaccines with high immunogenicity and safety is crucial for control of the global COVID-19 pandemic and prevention of further illness and fatalities. Here, we report development of SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the S protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG, as well neutralizing antibody in three animal models including Balb/C mice, Syrian hamsters, and non-human primate (Macaca leonina). In addition, the viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. No adverse effects were induced by Nanocovax in swiss mice (Musmusculus var. Albino), Rats (Rattus norvegicus), and New Zealand rabbits. These pre-clinical results indicated that Nanocovax is safe and effective.

immunology↗